VectivBio
Signal active
Organization
Contact Information
Overview
VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care.
It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.
About
Industries
Biotechnology, Health Care, Medical
Founded
2019
Employees
51-100
Headquarters locations
Switzerland, Europe
Social
N/A
Profile Resume
VectivBio headquartered in Switzerland, Europe, operates in the Biotechnology, Health Care, Medical sector. The company focuses on Biotechnology and has secured $23.9B in funding across 60 round(s). With a team of 51-100 employees, VectivBio is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - VectivBio, raised $125.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
5
Investors
11
Lead Investors
0
Total Funding Amount
$399.0M
Details
1
VectivBio has raised a total of $399.0M in funding over 1 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2020 | Early Stage Venture | 35.0M |
Investors
VectivBio is funded by 29 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Vivo Capital | - | FUNDING ROUND - Vivo Capital | 125.0M |
| Forbion Capital Partners | - | FUNDING ROUND - Forbion Capital Partners | 125.0M |
| VectivBio | - | FUNDING ROUND - VectivBio | 125.0M |
| OrbiMed | - | FUNDING ROUND - OrbiMed | 125.0M |
Recent Activity
There is no recent news or activity for this profile.